Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Cosentyx, Entresto, Kesimpta, Pluvicto, Scemblix ...

This strong performance led Novartis to upgrade its full-year 2024 guidance, with products like Kesimpta, Kisqali, and Cosentyx being key contributors to this growth. However, despite these ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release ... So moving to Slide 8, ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Swiss pharma giant Novartis AG NVS reported better-than-expected ... driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis is scheduled to report results for ... neuroscience medicine Kesimpta and cardiovascular drug Entresto--the patent of which expires in 2025--are expected to be the key drivers in the ...

Multiple sclerosis drug Kesimpta sales reached $838 million, up +28%, reflecting increased demand for a high-efficacy product with convenient self-administered dosing. Guidance: Novartis also ...